Literature DB >> 15990001

Differences in pulmonary function before vs. 1 year after hypofractionated stereotactic radiotherapy for small peripheral lung tumors.

Toshio Ohashi1, Atsuya Takeda, Naoyuki Shigematsu, Etsuo Kunieda, Akitoshi Ishizaka, Junichi Fukada, Hossain M Deloar, Osamu Kawaguchi, Toshiaki Takeda, Kazuhiko Takemasa, Kouichi Isobe, Atsushi Kubo.   

Abstract

PURPOSE: To evaluate long-term pulmonary toxicity of stereotactic radiotherapy (SRT) by pulmonary function tests (PFTs) performed before and after SRT for small peripheral lung tumors. METHODS AND MATERIALS: A total of 17 lesions in 15 patients with small peripheral lung tumors, who underwent SRT between February 2000 and April 2003, were included in this study. Twelve patients had primary lung cancer, and 3 patients had metastatic lung cancer. Primary lung cancer was T1-2N0M0 in all cases. Smoking history was assessed by the Brinkman index (number of cigarettes smoked per day multiplied by number of years of smoking). Prescribed radiation doses at the 80% isodose line were 40-60 Gy in 5-8 fractions. PFTs were performed immediately before SRT and 1 year after SRT. Test parameters included total lung capacity (TLC), vital capacity (VC), forced expiratory volume in 1 s (FEV1.0), and diffusing capacity of lung for carbon monoxide (DLCO). PFT changes were evaluated in relation to patient- and treatment-related factors, including age, the Brinkman index, internal target volume, the percentages of lung volume irradiated with >15, 20, 25, and 30 Gy (V15, V20, V25, and V30, respectively), and mean lung dose.
RESULTS: There were no significant changes in TLC, VC, or FEV1.0 before vs. after SRT. The mean percent change from baseline in DLCO was significantly increased by 128.2%. Univariate and multivariate analyses revealed a correlation between DLCO and the Brinkman index.
CONCLUSIONS: One year after SRT as compared with before SRT, there were no declines in TLC, VC, and FEV1.0. DLCO improved in patients who had been heavy smokers before SRT, suggesting a correlation between DLCO and smoking cessation. SRT seems to be tolerable in view of long-term lung function.

Entities:  

Mesh:

Year:  2005        PMID: 15990001     DOI: 10.1016/j.ijrobp.2004.12.050

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  15 in total

Review 1.  Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?

Authors:  Andrea Riccardo Filippi; Pierfrancesco Franco; Umberto Ricardi
Journal:  Rep Pract Oncol Radiother       Date:  2013-07-01

Review 2.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

Review 3.  Radiation pneumonitis after stereotactic radiation therapy for lung cancer.

Authors:  Hideomi Yamashita; Wataru Takahashi; Akihiro Haga; Keiichi Nakagawa
Journal:  World J Radiol       Date:  2014-09-28

4.  Risk of Pneumonitis After Stereotactic Body Radiation Therapy in Patients With Previous Anatomic Lung Resection.

Authors:  Jason T Hayes; Elizabeth A David; LiHong Qi; Allen M Chen; Megan E Daly
Journal:  Clin Lung Cancer       Date:  2015-01-31       Impact factor: 4.785

Review 5.  Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters.

Authors:  Anne G H Niezink; Renske A de Jong; Christina T Muijs; Johannes A Langendijk; Joachim Widder
Journal:  Oncologist       Date:  2017-05-26

6.  Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  Strahlenther Onkol       Date:  2016-10-25       Impact factor: 3.621

7.  Experimental stereotactic irradiation of normal rabbit lung: computed tomographic analysis of radiation injury and the histopathological features.

Authors:  Takatsugu Kawase; Etsuo Kunieda; Hossain M Deloar; Satoshi Seki; Akitomo Sugawara; Takanori Tsunoo; Eileen N Ogawa; Akitoshi Ishizaka; Kaori Kameyama; Atsuya Takeda; Atsushi Kubo
Journal:  Radiat Med       Date:  2007-11-26

Review 8.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Authors:  Feng-Ming Spring Kong; Vitali Moiseenko; Jing Zhao; Michael T Milano; Ling Li; Andreas Rimner; Shiva Das; X Allen Li; Moyed Miften; ZhongXing Liao; Mary Martel; Soren M Bentzen; Andrew Jackson; Jimm Grimm; Lawrence B Marks; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 8.013

Review 9.  Normal tissue toxicity after small field hypofractionated stereotactic body radiation.

Authors:  Michael T Milano; Louis S Constine; Paul Okunieff
Journal:  Radiat Oncol       Date:  2008-10-31       Impact factor: 3.481

10.  Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors.

Authors:  Brian T Collins; Kelly Erickson; Cristina A Reichner; Sean P Collins; Gregory J Gagnon; Sonja Dieterich; Don A McRae; Ying Zhang; Shadi Yousefi; Elliot Levy; Thomas Chang; Carlos Jamis-Dow; Filip Banovac; Eric D Anderson
Journal:  Radiat Oncol       Date:  2007-10-22       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.